CN115697348A - 通过透明质酸酶施用减少或抑制眼部损伤 - Google Patents

通过透明质酸酶施用减少或抑制眼部损伤 Download PDF

Info

Publication number
CN115697348A
CN115697348A CN202180040265.2A CN202180040265A CN115697348A CN 115697348 A CN115697348 A CN 115697348A CN 202180040265 A CN202180040265 A CN 202180040265A CN 115697348 A CN115697348 A CN 115697348A
Authority
CN
China
Prior art keywords
minutes
hyaluronidase
eye
hyaluronic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040265.2A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂夫·约林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Progress Co ltd
Original Assignee
Medical Progress Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Progress Co ltd filed Critical Medical Progress Co ltd
Publication of CN115697348A publication Critical patent/CN115697348A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
CN202180040265.2A 2020-04-02 2021-04-02 通过透明质酸酶施用减少或抑制眼部损伤 Pending CN115697348A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
US63/004,444 2020-04-02
PCT/US2021/025668 WO2021203062A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Publications (1)

Publication Number Publication Date
CN115697348A true CN115697348A (zh) 2023-02-03

Family

ID=77921064

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180040265.2A Pending CN115697348A (zh) 2020-04-02 2021-04-02 通过透明质酸酶施用减少或抑制眼部损伤

Country Status (11)

Country Link
US (1) US11878051B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125928A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521059A (cg-RX-API-DMAC7.html)
KR (1) KR20230005198A (cg-RX-API-DMAC7.html)
CN (1) CN115697348A (cg-RX-API-DMAC7.html)
AU (1) AU2021248653B2 (cg-RX-API-DMAC7.html)
CA (1) CA3174498A1 (cg-RX-API-DMAC7.html)
IL (1) IL296979A (cg-RX-API-DMAC7.html)
MX (1) MX2022012426A (cg-RX-API-DMAC7.html)
WO (1) WO2021203062A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003755A (es) * 2021-09-25 2024-04-15 Med Progress Llc Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa.
KR102922198B1 (ko) * 2022-04-25 2026-02-03 주식회사 메디팹 조직 수복용 생체재료의 분해 또는 교정용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257430A (zh) * 1997-05-22 2000-06-21 先进角膜系统公司 透明质酸酶在制备用于治疗眼科疾病中液化玻璃体液的眼用制剂中的应用
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257430A (zh) * 1997-05-22 2000-06-21 先进角膜系统公司 透明质酸酶在制备用于治疗眼科疾病中液化玻璃体液的眼用制剂中的应用
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE W,等: "Effectiveness of Retrobulbar Hyaluronidase Injection in an Iatrogenic Blindness Rabbit Model Using Hyaluronic Acid Filler Injection", PLAST RECONSTR SURG, vol. 144, no. 1, 31 July 2019 (2019-07-31), pages 142 - 143, XP093152396, DOI: 10.1097/PRS.0000000000005716 *

Also Published As

Publication number Publication date
ZA202211833B (en) 2023-04-26
WO2021203062A1 (en) 2021-10-07
JP2026065067A (ja) 2026-04-14
AU2021248653B2 (en) 2024-05-02
MX2022012426A (es) 2023-01-11
CA3174498A1 (en) 2021-10-07
EP4125928A1 (en) 2023-02-08
US20210308234A1 (en) 2021-10-07
IL296979A (en) 2022-12-01
US11878051B2 (en) 2024-01-23
EP4125928A4 (en) 2024-06-12
JP2023521059A (ja) 2023-05-23
AU2021248653A1 (en) 2022-12-01
KR20230005198A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
Kang-Mieler et al. Advances in ocular drug delivery systems
Cardillo et al. Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery
TW539560B (en) Ophthalmic drug delivery device
JP2026065067A (ja) ヒアルロニダーゼの投与による目の損傷の低減又は抑制
JP2019501200A (ja) 後眼部障害をアフリベルセプトおよびその他の生物製剤で処置するための方法およびデバイス
JP2017524677A (ja) 後眼部障害を処置するための方法およびデバイス
Ciulla et al. Microinjection via the suprachoroidal space: a review of a novel mode of administration.
Zhang et al. Endovascular hyaluronidase application through superselective angiography to rescue blindness caused by hyaluronic acid injection
US20210000919A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
Cuello-Rodríguez et al. Long acting injectables & implants: advances in intraocular drug delivery
CN101107006B (zh) 治疗黏连性关节囊炎的方法
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
CN118265537A (zh) 使用透明质酸酶施用减轻或抑制组织损伤
Spaide METHOD OF POVIDONE–IODINE APPLICATION AND ENDOPHTHALMITIS RISK
Loy et al. Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines
Barak et al. First-in-Human Clinical Evaluation of a Novel Nonsurgical Suprachoroidal Delivery Approach for Triamcinolone in Diabetic Macular Edema
Stubbs et al. Penetrating eye injury from a rigid infant pacifier
US20060034890A1 (en) Device for ocular delivery of active principles by the transpalpebral route
US20060116428A1 (en) Intravitreally-injectable solution for the treatment of vitreous hemorrhages
Lee et al. Posterior segment injury developed after injection of anesthetics on eyelids with needleless jet injection device
SU1683740A1 (ru) Способ введени лекарственных веществ дл лечени заболеваний глаз
KR20100109549A (ko) Tgf-베타 3을 사용한 흉터의 억제
RU2812900C2 (ru) Анестезирующая композиция и способ анестезирования глаза
Lu et al. Subconjunctival trypsin injection for anterior chamber fibrin exudates in eyes with globe rupture following vitrectomy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination